SCHEMBL5892452

SCHEMBL5892452

CC1(C)OB(c2ccc(Cl)s2)OC1(C)C

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LPL P06858 12/20 0.36
LIPG Q9Y5X9 12/20 0.36
P2RX7 Q99572 1/20 0.32
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA9 Q16790 2/20 0.31
CA12 O43570 1/20 0.31
CA3 P07451 1/20 0.31
CA4 P22748 1/20 0.31
CA6 P23280 1/20 0.31
CA5A P35218 1/20 0.31
CA7 P43166 1/20 0.31
CA14 Q9ULX7 1/20 0.31
CA5B Q9Y2D0 1/20 0.31
MAPK1 P28482 1/20 0.31
HCAR3 P49019 1/20 0.30
HCAR2 Q8TDS4 1/20 0.30
F11 P03951 1/20 0.30
USP30 Q70CQ3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120211 0.85 LPL (0.42) LPLLIPGP2RX7CA1CA2
SCHEMBL390494 0.79 LPL (0.40) LPLLIPGP2RX7CA1CA2
SCHEMBL30846 0.78 LPL (0.37) LPLLIPGP2RX7CA1CA2
SCHEMBL2400910 0.76 LPL (0.36) LPLLIPGP2RX7CA1CA2
SCHEMBL14854211 0.76 LPL (0.36) LPLLIPGP2RX7CA1CA2
SCHEMBL14332445 0.76 LPL (0.43) LPLLIPGP2RX7CA1CA2
SCHEMBL16001682 0.76 LPL (0.36) LPLLIPGP2RX7CA1CA2
SCHEMBL5892524 0.76 SNCA (0.33)
SCHEMBL3348299 0.73 LPL (0.36) LPLLIPGCA1CA2CA9
SCHEMBL586870 0.73 LPL (0.34) LPLLIPGP2RX7MAPK1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037905-B2 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2006-05-02 US claimed
US-20040053889-A1 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2004-03-18 US claimed
WO-2003105860-A1 PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF NOVO NORDISK A/S (DK) 2003-12-24 WO claimed
EP-4740948-A1 PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND Dong Wha Pharm. Co., Ltd. (KR) 2026-05-13 EP disclosed
US-20250059180-A1 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DONG WHA PHARM. CO., LTD. (KR) 2025-02-20 US disclosed
WO-2025008783-A1 PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND 동화약품주식회사 2025-01-09 WO disclosed
EP-4464701-A1 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Dong Wha Pharm. Co., Ltd. (KR) 2024-11-20 EP disclosed
EP-3694856-B1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2023-10-25 EP disclosed
WO-2023135564-A1 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 동화약품주식회사 2023-07-20 WO disclosed
EP-4175961-A1 HETEROCYCLENE DERIVATIVES AS PEST CONTROL AGENTS Bayer Aktiengesellschaft (DE) 2023-05-10 EP disclosed
US-20220324860-A1 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-10-13 US disclosed
US-20200392130-A1 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 US disclosed
US-20200113879-A1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-04-16 US disclosed
US-20100298609-A1 METHOD FOR PREPARING AN AROMATIC BORON REAGENT THROUGH BARBIER-TYPE REACTION TAMKANG UNIVERSITY (TW) 2010-11-25 US disclosed
US-20100298609-A1 METHOD FOR PREPARING AN AROMATIC BORON REAGENT THROUGH BARBIER-TYPE REACTION TAMKANG UNIVERSITY (TW) 2010-11-25 US disclosed
US-20100298575-A1 METHOD FOR PREPARING AN AROMATIC BORON REAGENT THROUGH BARBIER-TYPE REACTION TAMKANG UNIVERSITY (TW) 2010-11-25 US disclosed
US-20100298575-A1 METHOD FOR PREPARING AN AROMATIC BORON REAGENT THROUGH BARBIER-TYPE REACTION TAMKANG UNIVERSITY (TW) 2010-11-25 US disclosed
US-7037905-B2 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2006-05-02 US disclosed
US-20040053889-A1 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2004-03-18 US disclosed
WO-2003105860-A1 PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF NOVO NORDISK A/S (DK) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392130-A1 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN3B, GRIN3A LPL 3333/4885LIPG 4132/4885P2RX7 70/4885
US-20250059180-A1 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME CYP2C9, CYP1B1, SULT1A1 LPL 2984/4885LIPG 3537/4885P2RX7 834/4885
US-20100298609-A1 METHOD FOR PREPARING AN AROMATIC BORON REAGENT THROUGH BARBIER-TYPE REACTION BTD, BRD8, BROX LPL 3996/4885LIPG 4654/4885P2RX7 1789/4885
US-20040053889-A1 Pharmaceutical use of boronic acids and esters thereof LIPE, CEL, LIPA LPL 5/4885LIPG 8/4885P2RX7 2975/4885
US-20220324860-A1 SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN3B, GRIN3A LPL 3333/4885LIPG 4132/4885P2RX7 70/4885
US-20200113879-A1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SLC10A1, CYP11B2, CYP11B1 LPL 2171/4885LIPG 3362/4885P2RX7 3287/4885
US-20100298575-A1 METHOD FOR PREPARING AN AROMATIC BORON REAGENT THROUGH BARBIER-TYPE REACTION BTD, BRD8, BROX LPL 3996/4885LIPG 4654/4885P2RX7 1789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.